Physician profile
Nora K Tee
NPI 1003835679
$59,702.32
in general payments reported to CMS, 2019-2025
39 companies · $5,911 in 2025
The $5,911 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $3,777 · 2021: $7,051 · 2022: $6,524 · 2023: $6,257 · 2024: $9,851 · 2025: $5,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $6,479 · Travel and Lodging: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,240.00 |
| Food and Beverage | $6,478.50 |
| Travel and Lodging | $300.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $34,963.40 | 2019-2025 | Vemlidy |
| Amgen INC. | $9,307.42 | 2019-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $2,194.24 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,629.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,628.43 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $1,202.77 | 2019-2022 | |
| Abbvie INC. | $1,113.90 | 2019-2025 | Linzess, Viberzi, Creon |
| Pfizer INC. | $1,072.19 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $929.99 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $638.36 | 2019-2023 | Steglatro, Januvia, Belsomra |
| Astellas Pharma US INC | $520.27 | 2019-2023 | Myrbetriq |
| Abbott Laboratories | $462.95 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $431.40 | 2019-2025 | |
| Lilly USA, LLC | $413.17 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $408.15 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Tee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.